RICOVAI-19 is a gene therapy platform for multiple diseases. Examine each patient's health, including their condition and diagnosis, as well as prognosis.
An Italian artificial intelligence company called Almawave launched a pilot study this month for a wearable gadget that employs AI to help patients and healthcare workers during the COVID-19 outbreak.
The study is a collaboration between the company and various entities. To be precise: Polytechnic of the Marche, Ospedale Riuniti of Ancona, ASUR Marche, Vivisol and Aditech. At present the preliminary results have been published in medRxiv as a preprint not yet peer-reviewed.
Among the co-authors of the study: Marco Mazzanti the Cardiac Imaging Department at the Barts Heart Center Foundation Trust in London; Aldo Salvi, internal doctor in the emergency room of the Ospedali Riuniti hospital in Ancona, Italy; Stephanie Giacomini, general practitioner specialized in local medicine at the Single Regional Health Authority (ASUR).
Wearable (and Italian) artificial intelligence
RicovAI-19 uses artificial intelligence and machine learning technology to analyze each patient's status, including blood pressure, respiratory rate, body temperature and oxygen saturation. It also monitors the adherence of the patient's medical condition to diagnosis and prognosis, as well as the existence of COVID-19 or other diseases.
RicovAI-19 also calculates and sends clinical stability indicators to medical personnel so they can diagnose patients and prescribe treatment. It uses a mobile app and a portable wearable device, which patients will be able to access for free.
What is this technology for?
Such a platform could have many future developments. At present its objective fully falls within those of new generation medicine. This and other technologies aim to reduce emergency visits, to rethink remote medical care and the healthcare model in general.
Overall, wearable AI technology and telemedicine will be very useful, and Covid is just the first test.
